Quinsair is a prescription medication specifically formulated for the management of chronic pulmonary infections caused by Pseudomonas aeruginosa in adult patients with cystic fibrosis. It contains the active ingredient levofloxacin, which is a type of antibiotic belonging to the fluoroquinolone class. Quinsair works by killing the bacteria responsible for the infection, thereby reducing symptoms and preventing the infection from worsening. It is administered through inhalation, allowing the medication to directly reach the lungs where the infection resides. This targeted approach helps in maximizing the drug's efficacy while minimizing systemic side effects. Quinsair is typically used in patients who have not responded adequately to other antibiotic treatments, making it a crucial option for managing persistent infections in the cystic fibrosis population.